Your browser doesn't support javascript.
Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models.
Rosenke, Kyle; Jarvis, Michael A; Feldmann, Friederike; Schwarz, Benjamin; Okumura, Atsushi; Lovaglio, Jamie; Saturday, Greg; Hanley, Patrick W; Meade-White, Kimberly; Williamson, Brandi N; Hansen, Frederick; Perez-Perez, Lizette; Leventhal, Shanna; Tang-Huau, Tsing-Lee; Callison, Julie; Haddock, Elaine; Stromberg, Kaitlin A; Scott, Dana; Sewell, Graham; Bosio, Catharine M; Hawman, David; de Wit, Emmie; Feldmann, Heinz.
  • Rosenke K; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Jarvis MA; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Feldmann F; University of Plymouth, Plymouth, Devon, United Kingdom; The Vaccine Group Ltd, Plymouth, Devon, United Kingdom.
  • Schwarz B; Rocky Mountain Veterinary Branch and.
  • Okumura A; Laboratory of Bacteriology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Lovaglio J; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Saturday G; Rocky Mountain Veterinary Branch and.
  • Hanley PW; Rocky Mountain Veterinary Branch and.
  • Meade-White K; Rocky Mountain Veterinary Branch and.
  • Williamson BN; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Hansen F; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Perez-Perez L; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Leventhal S; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Tang-Huau TL; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Callison J; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Haddock E; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Stromberg KA; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Scott D; Laboratory of Bacteriology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Sewell G; Rocky Mountain Veterinary Branch and.
  • Bosio CM; Leicester School of Pharmacy, De Montfort University, Leicester, United Kingdom.
  • Hawman D; Laboratory of Bacteriology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • de Wit E; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
  • Feldmann H; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA.
JCI Insight ; 5(23)2020 12 03.
Article in English | MEDLINE | ID: covidwho-890008
ABSTRACT
We remain largely without effective prophylactic/therapeutic interventions for COVID-19. Although many human COVID-19 clinical trials are ongoing, there remains a deficiency of supportive preclinical drug efficacy studies to help guide decisions. Here we assessed the prophylactic/therapeutic efficacy of hydroxychloroquine (HCQ), a drug of interest for COVID-19 management, in 2 animal disease models. The standard human malaria HCQ prophylaxis (6.5 mg/kg given weekly) and treatment (6.5 mg/kg given daily) did not significantly benefit clinical outcome, nor did it reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model. Similarly, when used for prophylaxis or treatment, neither the standard human malaria dose (6.5 mg/kg) nor a high dose (50 mg/kg) of HCQ had any beneficial effect on clinical disease or SARS-CoV-2 kinetics (replication/shedding) in the Syrian hamster disease model. Results from these 2 preclinical animal models may prove helpful in guiding clinical use of HCQ for prophylaxis/treatment of COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 / Hydroxychloroquine Type of study: Prognostic study Topics: Traditional medicine Limits: Animals / Humans / Male Language: English Year: 2020 Document Type: Article Affiliation country: Jci.insight.143174

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 / Hydroxychloroquine Type of study: Prognostic study Topics: Traditional medicine Limits: Animals / Humans / Male Language: English Year: 2020 Document Type: Article Affiliation country: Jci.insight.143174